(Q82617075)
Statements
Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors (English)
25 November 2010
scientific article published on 25 November 2010
No description defined